Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07701993
PHASE3

A Pivotal Clinical Study to Investigate the Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)

Sponsor: GlaxoSmithKline

View on ClinicalTrials.gov

Summary

This study will investigate the safety and efficacy of efimosfermin alfa in participants with compensated cirrhosis due to MASH.

Official title: A Phase 3, Double-blind, Randomized, Placebo Controlled, 2-arm Study to Investigate the Safety and Efficacy of Efimosfermin Alfa Injection in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (NEBULA-1)

Key Details

Gender

All

Age Range

18 Years - 75 Years

Study Type

INTERVENTIONAL

Enrollment

1740

Start Date

2026-07-22

Completion Date

2033-08-24

Last Updated

2026-08-05

Healthy Volunteers

No

Interventions

DRUG

Efimosfermin alfa

Efimosfermin alfa (subcutaneous injection) will be administered.

DRUG

Placebo

Placebo (subcutaneous injection) will be administered.

Locations (1)

GSK Investigational Site

Miami, Florida, United States